Q2 FY2026 EarningsQ2 FY2026 results beat consensus on earnings but missed on cash burn: GAAP EPS was -$0.95 vs. -$1.02 expected, primarily driven by lower-than-anticipated R&D spending. While revenue remains at $0 as expected for this clinical-stage biopharmaceutical company, net loss of $8.5M was narrower than the $8.8M consensus. However, operating cash flow for the first half was a significant miss at -$19.2M vs. -$9.0M expected, and management issued a 'going concern' warning as existing resources are insufficient to fund the next 12 months.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Atossa Therapeutics(ATOS) the EBIT is -8.694 M (+3.83%), Beat estimate;the EPS is -0.95 (+9.52%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.01B3.83%
-0.01B0.14%
+0.00B3.97%
EPSExceed expectations
-0.959.52%
-1.0252.38%
+0.07507.14%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf